Imugene (ASX:IMU) received a notice of allowance from the Chinese patent office for City of Hope's patent application for the CD19-expressing oncolytic virus, onCARlytics, according to a Wednesday Australian bourse filing.
The patent protects the method of composition and method of use of onCARlytics through to 2038.
OnCARlytics is exclusively licensed to Imugene and is a CD19-expressing oncolytic virus that enters solid tumor cells, forcing them to express the CD19 protein on the cell surface, presenting a target for CD19-targeting therapies.
Its OASIS dose escalation trial of onCARlytics is being conducted at up to ten sites in the US, with up to around 40 patients proposed to take part.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。